The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma.
Pancreatic cancer
immunotherapy
metabolic reprogramming
systemic therapy
tumor microenvironment
Journal
Annals of pancreatic cancer
ISSN: 2616-2741
Titre abrégé: Ann Pancreat Cancer
Pays: China
ID NLM: 101724278
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
entrez:
9
12
2020
pubmed:
10
12
2020
medline:
10
12
2020
Statut:
ppublish
Résumé
Metastatic pancreatic adenocarcinoma remains one of the deadliest cancer diagnoses with 5-year survival rates as low as 3%. For decades, gemcitabine remained the mainstay of systemic therapy before the approvals of FOLFIRINOX and gemcitabine with nab-paclitaxel. Despite these advances in the early 2010s, almost all patients progress on systemic chemotherapy and significant effort is needed to identify novel therapeutic targets. A promising array of approaches is currently under investigation, enabled by deeper understanding of the immune system within the tumor microenvironment (TME) and of the key vulnerabilities in pathways essential for tumor survival. In this review, we will explore the different approaches to boost tumor immunity and to target tumor metabolic pathways that are currently under clinical investigation for systemic treatment, and highlight the promising therapeutic areas that may give rise to the next generation of therapies for pancreatic cancer.
Identifiants
pubmed: 33294843
doi: 10.21037/apc-2020-pda-05
pmc: PMC7720884
mid: NIHMS1650265
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : T32 CA071345
Pays : United States
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/apc-2020-pda-05). The focused issue “Systemic and Targeted Therapies for Pancreas Ductal Adenocarcinoma” was commissioned by the editorial office without any funding or sponsorship. CW served as the unpaid Guest Editor of the focused issue. CW reports grants and personal fees from IPSEN, outside the submitted work. The other authors have no conflicts of interest to declare.
Références
Clin Cancer Res. 2013 Jul 1;19(13):3404-15
pubmed: 23653148
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Oncoimmunology. 2015 Oct 29;5(4):e1102828
pubmed: 27141387
J Immunother. 2013 Sep;36(7):382-9
pubmed: 23924790
Oncologist. 2011;16(10):1397-402
pubmed: 21934105
Hum Vaccin Immunother. 2014;10(11):3354-68
pubmed: 25483688
Cancer Cell. 2016 Jun 13;29(6):832-845
pubmed: 27265504
Cancer Immunol Res. 2015 Apr;3(4):399-411
pubmed: 25678581
Pancreas. 2004 Jan;28(1):38-44
pubmed: 14707728
Cell. 2006 Nov 3;127(3):469-80
pubmed: 17081971
Science. 2011 Mar 25;331(6024):1612-6
pubmed: 21436454
Gastroenterology. 2013 Nov;145(5):1121-32
pubmed: 23891972
Oncoimmunology. 2016 Aug 19;5(9):e1214788
pubmed: 27757312
Eur J Cancer. 2016 Nov;68:156-162
pubmed: 27764686
Nat Commun. 2018 Nov 23;9(1):4945
pubmed: 30470748
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Nature. 1998 Jun 4;393(6684):478-80
pubmed: 9624004
Cancer Res. 2014 Sep 15;74(18):5057-69
pubmed: 25082815
Int J Hyperthermia. 2010;26(3):232-46
pubmed: 20388021
Clin Cancer Res. 2014 Aug 15;20(16):4370-80
pubmed: 24947925
Sci Transl Med. 2017 Oct 4;9(410):
pubmed: 28978752
Nature. 2014 Apr 3;508(7494):108-12
pubmed: 24670634
Ann Oncol. 1995 Feb;6(2):129-32
pubmed: 7786820
N Engl J Med. 2019 Mar 7;380(10):990
pubmed: 30855761
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7
pubmed: 24277834
Nat Med. 1999 Jul;5(7):774-9
pubmed: 10395322
Science. 2009 Jun 12;324(5933):1457-61
pubmed: 19460966
J Cancer Res Clin Oncol. 2019 Nov;145(11):2813-2822
pubmed: 31492985
JAMA Oncol. 2019 Jul 1;5(7):1020-1027
pubmed: 31145418
Future Oncol. 2018 Jan;14(1):13-22
pubmed: 29235360
Am J Pathol. 2010 Nov;177(5):2585-96
pubmed: 20934972
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Eur J Cancer. 1999 Dec;35(13):1851-61
pubmed: 10674003
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Nature. 2015 Feb 26;518(7540):495-501
pubmed: 25719666
Radiother Oncol. 2009 Sep;92(3):411-6
pubmed: 19616335
Clin Cancer Res. 2018 Mar 15;24(6):1287-1295
pubmed: 29298798
Nature. 1998 Jun 4;393(6684):474-8
pubmed: 9624003
Cancer Cell. 2012 Jun 12;21(6):822-35
pubmed: 22698406
Cancer Chemother Pharmacol. 1998;42(5):391-9
pubmed: 9771954
Nature. 2004 Nov 18;432(7015):332-7
pubmed: 15549095
Nature. 2016 Mar 3;531(7592):47-52
pubmed: 26909576
Nat Rev Cancer. 2010 Oct;10(10):683-95
pubmed: 20814421
Nat Rev Dis Primers. 2016 Apr 21;2:16022
pubmed: 27158978
Genes Dev. 2011 Mar 1;25(5):460-70
pubmed: 21317241
Cancer Discov. 2016 Aug;6(8):886-99
pubmed: 27184426
Nat Commun. 2013;4:2516
pubmed: 24084631
Cancer Res. 2016 May 1;76(9):2525-39
pubmed: 26980767
Cancer Discov. 2016 Aug;6(8):852-69
pubmed: 27246539
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Cancer Res. 2013 Feb 1;73(3):1128-41
pubmed: 23221383
Immunity. 2018 Jul 17;49(1):178-193.e7
pubmed: 29958801
Cancer Res. 2004 Feb 1;64(3):985-93
pubmed: 14871829
Nat Rev Clin Oncol. 2018 Aug;15(8):477-494
pubmed: 29872177
Cancer Discov. 2018 Sep;8(9):1096-1111
pubmed: 29903880
Lancet. 2016 Feb 6;387(10018):545-557
pubmed: 26615328
Clin Exp Metastasis. 2016 Mar;33(3):225-30
pubmed: 26589701
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
JAMA Oncol. 2019 Oct 3;:
pubmed: 31580386
Clin Gastroenterol Hepatol. 2008 Oct;6(10):1155-61
pubmed: 18639493
PLoS One. 2007 Nov 07;2(11):e1155
pubmed: 17982507
Cancer Cell. 2012 Mar 20;21(3):418-29
pubmed: 22439937
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3919-24
pubmed: 23407165
Pancreas. 1987;2(1):14-24
pubmed: 3554225
Mol Cancer Ther. 2019 Mar;18(3):613-620
pubmed: 30587556
Nat Rev Genet. 2019 Nov;20(11):657-674
pubmed: 31358977
Nat Immunol. 2018 Nov;19(11):1236-1247
pubmed: 30323345
Clin Cancer Res. 1999 May;5(5):1189-96
pubmed: 10353756
Gastroenterology. 2005 Apr;128(4):907-21
pubmed: 15825074
J Clin Oncol. 2018 Feb 1;36(4):359-366
pubmed: 29232172
Expert Rev Anticancer Ther. 2015;15(10):1223-31
pubmed: 26402249
J Clin Oncol. 2018 Jun 1;36(16):1611-1618
pubmed: 29437535
Tumour Biol. 2016 Jul;37(7):8657-64
pubmed: 26738860
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
Cancer Immunol Res. 2019 Mar;7(3):428-442
pubmed: 30642833
Nature. 2008 Sep 18;455(7211):406-10
pubmed: 18754008
Nat Rev Gastroenterol Hepatol. 2012 Aug;9(8):454-67
pubmed: 22710569
Annu Rev Immunol. 2015;33:445-74
pubmed: 25622193
Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2909-14
pubmed: 21282607
Int J Clin Oncol. 2017 Aug;22(4):726-733
pubmed: 28314962
PLoS One. 2018 Jun 7;13(6):e0198940
pubmed: 29879220
Genes Dev. 2011 Apr 1;25(7):717-29
pubmed: 21406549
IUBMB Life. 2014 Dec;66(12):835-46
pubmed: 25557640
Cell. 2019 Jun 27;178(1):160-175.e27
pubmed: 31155233
Clin Cancer Res. 2004 Feb 1;10(3):1121-9
pubmed: 14871992
Nature. 2015 Apr 16;520(7547):373-7
pubmed: 25754329
Ann Oncol. 2014 Sep;25(9):1750-1755
pubmed: 24907635
Oncol Rep. 2010 May;23(5):1183-92
pubmed: 20372829
Cancer Res. 2013 Aug 1;73(15):4909-22
pubmed: 23761328
Mol Cell. 2015 Nov 19;60(4):547-60
pubmed: 26590714
Nature. 2013 May 30;497(7451):633-7
pubmed: 23665962
J Immunother. 2010 Oct;33(8):828-33
pubmed: 20842054
Clin Cancer Res. 2012 Aug 15;18(16):4266-76
pubmed: 22896693
N Engl J Med. 2013 Jul 11;369(2):122-33
pubmed: 23724867
Biochim Biophys Acta. 2011 Jun;1807(6):552-61
pubmed: 20955683
Cancer Cell. 2017 Aug 14;32(2):185-203.e13
pubmed: 28810144
PLoS One. 2012;7(2):e31384
pubmed: 22348081
J Exp Med. 2004 Aug 2;200(3):297-306
pubmed: 15289501
PLoS One. 2016 Oct 12;11(10):e0164244
pubmed: 27732654
Cell Mol Life Sci. 2016 Apr;73(7):1333-48
pubmed: 26626411
Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12425-30
pubmed: 21746895
Int J Oncol. 2007 Apr;30(4):849-55
pubmed: 17332923
J Clin Oncol. 1997 Jun;15(6):2403-13
pubmed: 9196156
Future Oncol. 2019 Oct;15(28):3189-3196
pubmed: 31512497
Cancer Res. 2007 Oct 1;67(19):9518-27
pubmed: 17909062
Nature. 2016 Oct 20;538(7625):378-382
pubmed: 27732578
Biochem Pharmacol. 1998 Nov 15;56(10):1315-22
pubmed: 9825730
Oncol Lett. 2012 Dec;4(6):1151-1157
pubmed: 23226794
Lancet Oncol. 2015 Jul;16(7):839-47
pubmed: 26067687
Pancreas. 1995 Nov;11(4):357-64
pubmed: 8532652
Gastroenterology. 2013 Jun;144(6):1210-9
pubmed: 23622130
Clin Cancer Res. 2019 Jul 1;25(13):3934-3945
pubmed: 30940657
Br J Cancer. 2014 Sep 9;111(6):1132-8
pubmed: 25072261
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Sci Rep. 2017 Jul 19;7(1):5825
pubmed: 28724893
J Immunother. 2015 Jan;38(1):1-11
pubmed: 25415283
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):
pubmed: 29229669
Trends Immunol. 2018 Aug;39(8):644-655
pubmed: 30001871
Clin Cancer Res. 2016 Mar 1;22(5):1076-85
pubmed: 26459175
Nat Rev Clin Oncol. 2011 Feb;8(2):97-106
pubmed: 21151206
Gut. 2013 Jan;62(1):112-20
pubmed: 22466618
Nat Med. 1999 May;5(5):548-53
pubmed: 10229232
Cancer Chemother Pharmacol. 2007 Mar;59(4):447-54
pubmed: 16855842
Gut. 1999 Apr;44(4):534-41
pubmed: 10075961
Science. 1994 May 13;264(5161):961-5
pubmed: 7513904
Cancer Res. 2016 Jan 1;76(1):35-42
pubmed: 26573801
JAMA Oncol. 2019 Jul 1;5(7):993-998
pubmed: 31120501
J Immunother Cancer. 2018 Jun 4;6(1):46
pubmed: 29866197
Cell. 2012 Apr 27;149(3):656-70
pubmed: 22541435
Nature. 1998 Jun 4;393(6684):480-3
pubmed: 9624005
Oncotarget. 2016 Aug 2;7(31):50735-50754
pubmed: 27191744
Lancet Oncol. 2017 Jun;18(6):770-778
pubmed: 28495639
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Ann Oncol. 2004 Mar;15(3):467-73
pubmed: 14998850
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Clin Cancer Res. 2015 Aug 1;21(15):3561-8
pubmed: 25695692
Sci Adv. 2016 May 27;2(5):e1600200
pubmed: 27386546
Clin Cancer Res. 2008 Oct 1;14(19):5995-6004
pubmed: 18829478
Biomed Res Int. 2014;2014:817613
pubmed: 25147816
Clin Cancer Res. 2017 Oct 1;23(19):5703-5710
pubmed: 28655795
Oncotarget. 2014 Jan 30;5(2):403-16
pubmed: 24480782
Cancer Chemother Pharmacol. 2015 Sep;76(3):489-498
pubmed: 26126726